All In Biotech

Drug Trial Radar · NCT05815862

Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

A Multi-cohort, Randomized, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AL2846 Capsules in Treated Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Feb 15, 2023

Primary completion

Aug 20, 2025

Study completion Aug 20, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer. Objective response rate (ORR) and progression-free survival (PFS) are the primary endpoints.

Conditions

  • Advanced Lung Cancer
  • Ovarian Cancer

Interventions

  • AL2846 capsuleDrug

    AL2846 is a multi-target tyrosine kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rate (ORR)Time frame: From baseline up to 12 months.
  2. Progression free survival (PFS)Time frame: From baseline up to 12 months.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.